Abstract
Purpose
Chemotherapy is the mainstay treatment for advanced poorly differentiated gastrointestinal neuroendocrine carcinoma (GI-NEC), with platinum-containing regimens being the optimal first-line regimen. However, the role and efficacy of second-line chemotherapy for GI-NEC are unclear. This study aimed to evaluate the feasibility and efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line therapy in patients with relapsed or recurrent GI-NEC after first-line platinum plus etoposide therapy.
Methods
We retrospectively evaluated eight consecutive patients with unresectable GI-NEC treated between 2017 and 2020. The inclusion criteria were pre-treatment with platinum doublet therapy, performance status (PS) 0–2, having measurable lesions, and treatment with FOLFIRI as second-line therapy. The overall response rate, progression-free survival (PFS), overall survival (OS), safety, and relative dose intensity were evaluated.
Results
Five patients met the inclusion criteria. Overall, 37 cycles of FOLFIRI were administered. The relative dose intensities for irinotecan, continuous infusion of 5-FU, and a bolus injection of 5-FU were 76%, 72%, and 54%, respectively. Overall, 2 of the 5 patients achieved partial response (40%), and the duration of response (DOR) was 4.0 months. The PFS and OS rates were 5.8 (95% CI, 1.5-NA) and 11 (95% CI, 6.3-NA) months, respectively. Overall, 4 of the 5 patients (80%) proceeded with further chemotherapy. Grade ≥ 3 adverse events except hematological toxicity included febrile neutropenia (n = 2), anorexia (n = 2), and fatigue (n = 1). Treatment discontinuation due to treatment-related adverse events was not observed.
Conclusions
FOLFIRI showed modest efficacy and feasibility for GI-NEC patients and has thus potential for patients who fail the first-line treatment.
Similar content being viewed by others
References
Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008;87:40–6. https://doi.org/10.1159/000109976.
Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev. 2013;39:270–4. https://doi.org/10.1016/j.ctrv.2012.06.009.
Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5. https://doi.org/10.1038/sj.bjc.6690325.
Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313–8. https://doi.org/10.1093/jjco/hyp173.
von Pawel J, Jotte R, Spigel DR, O'Brien MER, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012–9. https://doi.org/10.1200/jco.2013.54.5392.
Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401–6. https://doi.org/10.1200/jco.2008.18.1974.
Postmus PE, Berendsen HH, van Zandwijk N, Splinter TAW, Burghouts JTM, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–11. https://doi.org/10.1016/0277-5379(87)90128-3.
Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, et al. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study. Cancer Manag Res. 2019;11:5757–64. https://doi.org/10.2147/cmar.s201048.
Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, et al. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anti-Cancer Drugs. 2016;27:794–9. https://doi.org/10.1097/cad.0000000000000393.
Nio K, Arita S, Isobe T, Kusaba H, Kohashi K, Kajitani T, et al. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemother Pharmacol. 2015;75:829–35. https://doi.org/10.1007/s00280-015-2706-y.
Asayama M, Fuse N, Yoshino T, Yano T, Tahara M, Doi T, et al. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. Cancer Chemother Pharmacol. 2011;68:1325–30. https://doi.org/10.1007/s00280-011-1619-7.
Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, et al. Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma. Gastroenterol Res Pract. 2015;2015:425876–5. https://doi.org/10.1155/2015/425876.
Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19:751–7. https://doi.org/10.1530/erc-12-0002.
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8. https://doi.org/10.1111/his.13975.
Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853–60. https://doi.org/10.1016/s1470-2045(10)70181-9.
Fuse N, Doi T, Ohtsu A, Yano T, Hamamoto Y, Minashi K, et al. Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol. 2008;13:144–9. https://doi.org/10.1007/s10147-007-0737-z.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.
Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, et al. Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Sci Rep. 2016;6:18999. https://doi.org/10.1038/srep18999.
Sato I, Ueda N, Kinoshita E, et al. Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy. Gan To Kagaku Ryoho. 2010;37:1341–4.
Wang L, Song Q, Li J, Chen X. S-1 treatment leading to complete remission of advanced duodenal adenocarcinoma: a case report. Mol Clin Oncol. 2015;3:1184–6. https://doi.org/10.3892/mco.2015.607.
Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K, et al. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. Anticancer Res. 2014;34:5743–7.
Acknowledgments
The authors thank Editage (www.editage.jp) for English language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
The study was approved by the Institutional Review Board (No. 2020-002).
Informed Consent
The need for informed consent was waived owing to the retrospective nature of the study. An opt-out option was provided instead.
Consent for Publication
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sugiyama, K., Shiraishi, K., Sato, M. et al. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma. J Gastrointest Canc 52, 947–951 (2021). https://doi.org/10.1007/s12029-020-00516-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-020-00516-7